The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
In 1958 Pius XII approved of the image in association with the devotion to the Holy Face of Jesus, and decreed that the "Feast of the Holy Winding Sheet of Christ" be celebrated every year on Shrove Tuesday. In 1936 Pius XII had referred to the Shroud as a "holy thing perhaps like nothing else". In 1998 Pope John Paul II called the Shroud a "distinguished relic" and "a mirror of the Gospel". His successor, Pope Benedict XVI, called it an "icon written with the blood of a whipped man, crowned with thorns, crucified and pierced on his right side". In 2013 Pope Francis referred to it as an "icon of a man scourged and crucified". In 1983, archbishops of the Catholic Church and Greek Orthodox Church, as well as clergy of several Protestant churches attended a prayer service at the Shroud exhibit in Turin, where they "offered their corporate blessing" to the exhibit. In 1983 the Shroud was given to the Holy See by the House of Savoy. However, as with all relics of this kind, the Roman Catholic Church made no pronouncements on its authenticity. As with other approved Catholic devotions, the matter has been left to the personal decision of the faithful, as long as the Church does not issue a future notification to the contrary. In the Church's view, whether the cloth is authentic or not has no bearing whatsoever on the validity of what Jesus taught or on the saving power of his death and resurrection. Pope John Paul II stated in 1998 that: "Since it is not a matter of faith, the Church has no specific competence to pronounce on these questions.
=== Nanorecording === In a nanorecording application, a certain rotaxane is deposited as a Langmuir–Blodgett film on ITO-coated glass. When a positive voltage is applied with the tip of a scanning tunneling microscope probe, the rotaxane rings in the tip area switch to a different part of the dumbbell and the resulting new conformation makes the molecules stick out 0.3 nanometer from the surface. This height difference is sufficient for a memory dot. It is not yet known how to erase such a nanorecording film.
On 25 August, Israel began strikes in southern Lebanon against Hezbollah targets. Israel framed its strikes as "preemptive". Hezbollah said that it fired over 320 Katyusha rockets to IDF sites in northern Israel and the Golan Heights as the first phase of response to the assassination of Fuad Shukr. A woman was slightly injured due to sharpnel from the attack in Acre. Some homes were also damaged in Northern Israel. Israel sent a hundred fighter jets during its operations. Israeli Defense Minister Yoav Gallant described the strikes as "very successful", stating that "over fifty percent, maybe two-thirds" of Hezbollah's strikes were prevented. An Israeli drone strike in Qasimia in southern Lebanon wounded two people including one Hezbollah militant.
==== Rare-earth mining ==== Due to natural occurrence of radioactive elements such as thorium and radium in rare-earth ore, mining operations also result in production of waste and mineral deposits that are slightly radioactive.
Glucagon is a hormone that generally opposes the action of insulin. It increases blood glucose by stimulating the production of glucose in the liver via glycogenolysis (breakdown of glycogen) and gluconeogenesis (production of glucose from non-carbohydrate sources). Glucagon also increases the breakdown of lipids and amino acids and the production of ketones. Unlike currently approved weight loss drugs, glucagon receptor agonists increase energy expenditure. Combination GLP-1/glucagon receptor agonists provide the thermogenic benefits of glucagon activation while almost eliminating hyperglycemia induced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse effects have hampered development. The most advanced of these drugs is mazdutide which is in a phase III trial as of 2023.
Sources: en.wikipedia.org
Soy sauce (醬油, jiàngyóu) is considered almost as old as soy paste—a type of fermented paste (jiàng, 醬) obtained from soybeans—which had appeared during the Western Han dynasty (206 BC – 220 AD) and was listed in the bamboo slips found in the archaeological site Mawangdui (馬王堆). There are several precursors of soy sauce that are associated products with soy paste. The oldest is qingjiang (清醬), which appeared in AD 40 and was listed in Simin Yueling (四民月令). Others are jiangqing (醬清), chizhi (豉汁) and chiqing (豉清), which were recorded in the Qimin Yaoshu (齊民要術) in AD 540. By the time of the Song dynasty (960–1279 AD), the term jiàng yóu (醬油) had become the accepted name for the liquid condiment, documented in two books: Shanjia Qinggong (山家清供) and Pujiang Wushi Zhongkuilu (浦江吳氏中饋錄) during the Song dynasty (960–1279 AD). Like many salty condiments, soy sauce was originally a way to stretch salt, historically an expensive commodity. During the Zhou dynasty of ancient China, fermented fish with salt was used as a condiment in which soybeans were included during the fermentation process. By the time of the Han dynasty, this had been replaced with the recipe for soy paste and its by-product soy sauce, by using soybeans as the principal ingredient, with fermented fish-based sauces developing separately into fish sauce.
The Boer government later handed the men over to the British for trial and the British prisoners were returned to London. A few days after the raid, the Kaiser of Germany sent a telegram (the "Kruger telegram") congratulating President Kruger and the Transvaal government on their success "without the help of friendly powers", alluding to potential support by Germany. When this was disclosed in the British press, it raised a storm of anti-German feeling. Dr. Jameson was lionised by the press and London society, inflamed by anti-Boer and anti-German feeling and in a frenzy of jingoism. Jameson was sentenced to 15 months for leading the raid, which he served in Holloway Prison, while his second-in-command Willoughby was sentenced to 10 months.. The Transvaal government was paid almost £1 million in compensation by the British South Africa Company. For conspiring with Jameson, the members of the Reform Committee (Transvaal), including Colonel Frank Rhodes and John Hays Hammond, were jailed in deplorable conditions, found guilty of high treason, and sentenced to death by hanging. This sentence was later commuted to 15 years' imprisonment, and in June 1896, all surviving members of the committee were released on payment of stiff fines. As further punishment for his support of Jameson, the highly decorated Col. Rhodes was placed on the retired list by the British Army and barred from active involvement in army business.
=== General election 2005 === After the 2004 European Parliamentary election results became known, in which Galloway stood in London, but did not gain a seat, he announced that he would stand in East London at the next general election. On 2 December, he confirmed that he was aiming to be nominated as the Respect Party candidate for Bethnal Green and Bow. The ensuing electoral campaign in the seat proved to be a difficult one with heated exchanges between Galloway, Oona King (the incumbent Labour MP for Bethnal Green and Bow), and their respective supporters. Galloway and Respect threatened to sue King, whose mother is Jewish, if she repeated her assertion in the Evening Standard on 10 April 2005 which reported her as saying: "I have been told by several people that members of Respect have told Muslim voters 'not to vote for me because I am Jewish'". A major issue of the campaign was King's support for the Iraq War. Galloway was asked at a hustings early in the campaign why he was standing against one of only two black female MPs to which he replied that King had "voted to kill a lot of women in the last few years. Many of them had much darker skins than her". Claiming to be the ghost of Old Labour, Galloway told The Sunday Times contributor A. A. Gill that "we're here to haunt new Labour". Bethnal Green and Bow is "where Labour was founded. We're giving birth to the Labour Party all over again". Galloway said at a hustings event that the Labour Government had been pursuing a "war on Muslims" while King said her stance against Saddam Hussein had been "principled".
Her two manuscripts on form A DNA reached Acta Crystallographica in Copenhagen on 6 March 1953, one day before Crick and Watson had completed their model. The X-ray diffraction images collected by Gosling and Franklin provided the best evidence for the helical nature of DNA. Before this, both Linus Pauling, Watson, and Crick had generated erroneous models with the chains inside and the bases pointing outwards. Her experimental results provided estimates of the water content of DNA crystals, and these results were most consistent with the three sugar-phosphate backbones being on the outside of the molecule. Franklin's X-Ray photograph showed that the backbones had to be on the outside. Although she at first insisted vehemently that her data did not force one to conclude that DNA has a helical structure, in the drafts she submitted in 1953 she argues for a double helical DNA backbone. Building on her manuscripts, she discovered that form A DNA had antiparallel backbones, which supported the double helical structure of DNA. She did this through identification of the space group for DNA crystals. This would go to help Watson and Crick decide to look for DNA models with two antiparallel polynucleotide strands. In summary, Watson and Crick had three sources for Franklin's unpublished data: 1) her 1951 seminar, attended by Watson, 2) discussions with Wilkins, who worked in the same laboratory with Franklin, 3) a research progress report that was intended to promote coordination of Medical Research Council–supported laboratories.
Gunman Chronicles is a 2000 first-person shooter game originally created as a mod by the now-defunct Rewolf Software. It was originally a Quake deathmatch mod named Gunmanship 101, then it was moved to Quake II's engine before becoming a Half-Life mod. Gunman Chronicles was popular at the Half-Life Mod Expo in 1999, and Sierra approached Rewolf to make a retail version. After significant work, it was released as a standalone game. Plans were drawn to release Gunman Chronicles on GameCube, but it was never released.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.